Arrayit Corporation Wins Contract With Austrian Institute of Technology for Detection of Highly Dangerous Pathogens

SUNNYVALE, CA--(Marketwire - September 28, 2009) - Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences and technology leader, disclosed that its Microarray Platform has been adopted by Austrian Institute of Technology.

Our generation is challenged by existing and emerging microbial threats which can lead to ecological, economic and political crisis. The Austrian Institute of Technology is dedicated to availing these threats, in part, by utilizing state-of-the-art molecular tools for microbial diagnostics.

The Institute claims a profound and broad microarray experience, including genotyping, gene expression, DNA methylation, antibody and protein microarrays. Arrayit Corporation is proud to engage the Arrayit Microarray Platform in the service of the Institute. The Institute’s microarray based efforts will also deliver system-integrated bio and nanosensors that improve medical diagnostics and therapy, ensure better food control and help to sustain a clean environment.

Austrian Institute of Technology Microarray Technology Applications Link:

http://www.arcs.ac.at/health_environment/health_environment_area1_en.html

About Arrayit Corporation

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 650 products to a customer base, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.

Safe Harbor Statement

Except for historical information contained herein, statements made in this release that constitute forward-looking statements are based on currently available information, involve certain risks and uncertainties and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. Risks that may result from changes in the Company’s business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company’s Form 10-K/A for the fiscal year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended March 31, 2009 and Form 10-Q/A for the fiscal third quarter ended September 30, 2008.